Blastic plasmacytoid dendritic cell neoplasm: a short review and update
https://doi.org/10.4081/dr.2021.9781
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic neoplasm (less than 1% of primary cutaneous lymphomas and acute leukemia) with a highly aggressive clinical course and frequent skin, bone marrow and central nervous system (CNS) involvement. Despite a frequent initial response to chemotherapy, relapses with eventual leukemic dissemination are extremely common, leading to poor outcomes and a median overall survival (OS) ranging from 8 to 14 months in first line setting, with standard combination chemotherapy regimens. The skin is the first affected site (in almost 90% of patients) where BPDCN may remain confined for weeks or even months (sanctuary?) until a rapid second step with multiorgan involvement occurs. Therefore, it is of uppermost importance to suspect and recognize early skin lesions and to perform and report a skin biopsy as soon as possible. A multidisciplinary approach with coordination among dermatologists, pathologists and hematologists is definitively crucial in diagnosis and management of BPDCN.
Pagano, L., Valentini, C.G., Grammatico, S. and Pulsoni, A. (2016), Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol, 174: 188-202. https://doi.org/10.1111/bjh.14146 DOI: https://doi.org/10.1111/bjh.14146
Facts about Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia & Lymphoma Society, revised July 2019
NCCN guidelines, version 3.2021. Blastic Plasmacytoid Dendritic Cell Neoplasm (Age ≥ 18 years)
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv (2019) 3 (24): 4238–4251. https://doi.org/10.1182/bloodadvances.2019000647 DOI: https://doi.org/10.1182/bloodadvances.2019000647
Mohamed A. Kharfan-Dabaja, Naveen Pemmaraju, Mohamad Mohty et al Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies Clinical Hematology International Vol. 1(1), March 2019, pp. 2–9 DOI: https://doi.org/10.2991/chi.d.190218.001; eISSN: 2590-0048 DOI: https://doi.org/10.2991/chi.d.190218.001
Kamel Laribi, Alix Baugier de Materre, Mohamad Sobh, Lorenzo Cerroni, Caterina Giovanna Valentini, Tomohiro Aoki, Ritsuro Suzuki, Kengo Takeuchi, Arthur E. Frankel, Carlo Cota, David Ghez, Ronan Le Calloch, Livio Pagano, Tony Petrella; Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv 2020; 4 (19): 4838–4848. doi: https://doi.org/10.1182/bloodadvances.2020002474 DOI: https://doi.org/10.1182/bloodadvances.2020002474
Pagano L, Valentini C G et al, Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study, Haematologica 2013 Feb;98(2):239-46. doi10.3324/haematol.2012.072645. Epub 2012 Oct 12. DOI: https://doi.org/10.3324/haematol.2012.072645
Pemmaraju N, Lane A et al, Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm, N Engl J Med 2019; 380:1628-1637, DOI: 10.1056/NEJMoa1815105 DOI: https://doi.org/10.1056/NEJMoa1815105
Elzonris® (tagraxofusp). CHMP Assessment Report. Nov 2020
Alfayez M, Konopleva M, Pemmaraju N. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opin Biol Ther. 2020 Feb;20(2):115-123. doi: 10.1080/14712598.2020.1701651. Epub 2019 Dec 17. PMID: 31801379. DOI: https://doi.org/10.1080/14712598.2020.1701651
Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dompmartin A, d'Incan M, Maubec E, Grange F, Dereure O, Prey S, Barete S, Wetterwald M, Fraitag S, Petrella T. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010 Jan;162(1):74-9. doi: 10.1111/j.1365-2133.2009.09373.x. Epub 2009 Jun 22. PMID: 19689477. DOI: https://doi.org/10.1111/j.1365-2133.2009.09373.x
Tomohiro Aoki, Ritsuro Suzuki, Yachiyo Kuwatsuka, Shinichi Kako, Katsuya Fujimoto, Jun Taguchi, Tadakazu Kondo, Kinya Ohata, Toshiro Ito, Yoshimasa Kamoda, Takahiro Fukuda, Tatsuo Ichinohe, Kengo Takeuchi, Koji Izutsu, Junji Suzumiya; Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood 2015; 125 (23): 3559–3562. doi: https://doi.org/10.1182/blood-2015-01-621268 DOI: https://doi.org/10.1182/blood-2015-01-621268
Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis Mohamed A. Kharfan-Dabaja Tea Reljic Hemant S. Murthy Ernesto Ayala Ambuj Kumar Published:August 01, 2018DOI:https://doi.org/10.1016/j.clml.2018.07.295 DOI: https://doi.org/10.1016/j.clml.2018.07.295
Sullivan JM, Rizzieri DA. Hematology Am Society Hematol Educ Program 2016;2016:16-23 DOI: https://doi.org/10.1182/asheducation-2016.1.16
Montero J, Stephansky J, Cal T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL-2 and sensitive to venetoclax. Cancer Discov. 2017;7:156-64. DOI: https://doi.org/10.1158/2159-8290.CD-16-0999
DiNardo C, Rausch C R et al, Clinical Experience with the BCL-2 inhibitor venetoclax in combination therapy for relapsed and refractory AML and related myeloid malignancies; AM J Hematol. 2018;93:401-407 DOI: https://doi.org/10.1002/ajh.25000
Sapienza MR, Pileri A, Derenzini E, Melle F, Motta G, Fiori S, Calleri A, Pimpinelli N, Tabanelli V, Pileri S. Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects. Cancers (Basel). 2019 Apr 28;11(5):595. doi: 10.3390/cancers11050595. PMID: 31035408; PMCID: PMC6562663.
Yelena Kovtun, Gregory E. Jones, Sharlene Adams, Lauren Harvey, Charlene A. Audette, Alan Wilhelm, Chen Bai, Lingyun Rui, Rassol Laleau, Fenghua Liu, Olga Ab, Yulius Setiady, Nicholas C. Yoder, Victor S. Goldmacher, Ravi V. J. Chari, Jan Pinkas, Thomas Chittenden; A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv 2018; 2 (8): 848–858. doi: https://doi.org/10.1182/bloodadvances.2018017517 DOI: https://doi.org/10.1182/bloodadvances.2018017517
Khwaja, R, Daly, A, Wong, M, Mahe, E, Cerquozzi, S, Owen, C. Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a r
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju, Kendra L. Sweet, Anthony S. Stein, Eunice S. Wang, David A. Rizzieri, Sumithira Vasu, Todd L. Rosenblat, Christopher L. Brooks, Nassir Habboubi, Tariq I. Mughal, Hagop Kantarjian, Marina Konopleva, and Andrew A. Lane
Journal of Clinical Oncology 2022 40:26, 3032-3036eport of 3 cases. Leuk Lymphoma
Deconinck et al., Preliminary Results from an Observational Multicenter Study of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Tagraxofusp in the European Expanded Access Program; Poster presentation #3623, ASH 20222016;57;2720–22.
Naveen Pemmaraju, Nathaniel R. Wilson, Joseph D. Khoury, Nitin Jain, Naval Daver, Sherry Pierce, Elias Jabbour, Tapan Kadia, Courtney DiNardo, Guillermo Garcia-Manero, Muzaffar Qazilbash, Marina Konopleva, Hagop Kantarjian; Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood 2021; 138 (15): 1373–1377. doi: https://doi.org/10.1182/blood.2021011817 DOI: https://doi.org/10.1182/blood.2021011817
Martın-Martın L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7(9):10174-10181. DOI: https://doi.org/10.18632/oncotarget.7101
Outcomes of CNS involvement in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Irl Brian Greenwell, James Davis, Hong Li, Deborah Soong, Justin Taylor, Andrew A. Lane, and David Rizzieri Journal of Clinical Oncology 2021 39:15_suppl, e19043-e19043 DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.e19043
TAGRAXOFUSP IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM WITH/WITHOUT CENTRAL NERVOUS SYSTEM INVOLVEMENT AND INTRATHECAL CHEMOTHERAPY AS PRIMARY TREATMENT OR PROPHYLAXIS: AN ITALIAN EXPERIENCE, Rivoli G et al, EHA 2022, p#530
Marmouset, V, Joris, M, Merlusca, L, et al. The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm. Hematological Oncology. 2019; 37: 487– 489. https://doi.org/10.1002/hon.2671 DOI: https://doi.org/10.1002/hon.2671
Laribi, K, Denizon, N, Ghnaya, H, et al. Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine. Eur J Haematol 2014;93;81–5. DOI: https://doi.org/10.1111/ejh.12294
Ascani S, Massone C, Ferrara G, Rongioletti F, Papini M, Pileri S, Cerroni L. CD4-negative variant of CD4+/CD56+ hematodermic neoplasm: description of three cases. J Cutan Pathol. 2008 Oct;35(10):911-5. doi: 10.1111/j.1600-0560.2007.00915.x. Epub 2008 May 20. PMID: 18494823. DOI: https://doi.org/10.1111/j.1600-0560.2007.00915.x
Brody, J.P., Allen, S., Schulman, P., Sun, T., Chan, W.C., Friedman, H.D., Teichberg, S., Koduru, P., Cone, R.W. & Loughran, T.P. Jr (1995) Acute agranular CD4-positive natural killer cell leukemia: comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents. Cancer, 75, 2474–2483. DOI: https://doi.org/10.1002/1097-0142(19950515)75:10<2474::AID-CNCR2820751013>3.0.CO;2-Y
Chan, J.K.C., Jaffe, E.S. & Ralfkiaer, E. (2001) Blastic NK-cell lymphoma. In: WHO Classification. Tumors of Haematopoietic and Lymphoid Tissues (ed. by E.S. Jaffe, N.L. Harris, H. Stein, & J. W Vardiman), pp. 214–215. IARC Press, Lyon, France.
Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, Metze D, Fink-Puches R, Wiesner T, Cerroni L. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010 Jan;34(1):75-87. doi: 10.1097/PAS.0b013e3181c5e26b. PMID: 19956058. DOI: https://doi.org/10.1097/PAS.0b013e3181c5e26b
Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016 Feb;29(2):98-111. doi: 10.1038/modpathol.2015.145. Epub 2016 Jan 8. PMID: 26743477. DOI: https://doi.org/10.1038/modpathol.2015.145
Facchetti, F., Jones, D. & Petrella, T. (2008) Blastic plasmacytoid dendritic cell neoplasm. In: WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (eds. by Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W.), pp. 145–147. IARC press, Lyon, France.
Facchetti F, Pileri SA, Lorenzi L, Tabanelli V, Rimsza L, Pittaluga S, Dirnhofer S, Copie-Bergman C, de Leval L, Rosenwald A, Wotherspoon A, Fend F. Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. Virchows Arch. 2017 Oct;471(4):467-489. doi: 10.1007/s00428-017-2176-1. Epub 2017 Jul 10. PMID: 28695297. DOI: https://doi.org/10.1007/s00428-017-2176-1
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022;36: 1703-19. DOI: https://doi.org/10.1038/s41375-022-01613-1
Lennert K, Remmele W. Karyometrische untersuchungen an lymphknotenzellen des menschen. Acta Haematol 1958;19:99-113. DOI: https://doi.org/10.1159/000205419
Massone C, Lozzi GP, Egberts F, Fink-Puches R, Cota C, Kerl H, Cerroni L. The protean spectrum of non-Hodgkin lymphomas with prominent involvement of subcutaneous fat. J Cutan Pathol. 2006 Jun;33(6):418-25. doi: 10.1111/j.0303-6987.2006.00493.x. PMID: 16776717. DOI: https://doi.org/10.1111/j.0303-6987.2006.00493.x
Massone C, Chott A, Metze D, Kerl K, Citarella L, Vale E, Kerl H, Cerroni L. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol. 2004 Jun;28(6):719-35. doi: 10.1097/01.pas.0000126719.71954.4f. PMID: 15166664. DOI: https://doi.org/10.1097/01.pas.0000126719.71954.4f
Massone C, Raiola AM, Dominietto A, Minetto P, Beltramini S, Cerroni L, Sola S, Angelucci E. Blastic Plasmacytoid Dendritic Cell Neoplasm: Underlining the importance of an early diagnosis and the use of tagraxofusp therapy before wide dissemination. Australas J Dermatol. 2021 May;62(2):e316-e318. doi: 10.1111/ajd.13399. Epub 2020 Aug 5. PMID: 32757292. DOI: https://doi.org/10.1111/ajd.13399
Pagano L, Zinzani PL, Pileri S, Quaglino P, Cuglievan B, Berti E, Pemmaraju N, Onida F, Willemze R, Orfao A, Barosi G. Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel. Hemasphere. 2023 Feb 21;7(3):e841. doi: 10.1097/HS9.0000000000000841. PMID: 36844178; PMCID: PMC9946418. DOI: https://doi.org/10.1097/HS9.0000000000000841
Petrella, T., Dalac, S., Maynadie, M., Mugneret, F., Thomine, E., Courville, P., Joly, P., Lenormand, B., Arnould, L., Wechsler, J., Bagot, M., Rieux, C., Bosq, J., Avril, M.F., Bernheim, A., Molina, T., Devidas, A., Delfau-Larue, M.H., Gaulard, P. & Lambert, D. (1999) CD4 + CD56 + cutaneous neoplasms: a distinct hematological entity? Groupe Francais d’Etude des Lymphomes Cutanes (GFELC). The American Journal of Surgical Pathology, 23, 137–146. DOI: https://doi.org/10.1097/00000478-199902000-00001
Pileri A, Delfino C, Grandi V, Agostinelli C, Pileri SA, Pimpinelli N. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary. G Ital Dermatol Venereol. 2012 Dec;147(6):603-8. PMID: 23149706.
Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol. 2011;29:163. DOI: https://doi.org/10.1146/annurev-immunol-031210-101345
Sapienza MR, Pileri A, Derenzini E, Melle F, Motta G, Fiori S, Calleri A, Pimpinelli N, Tabanelli V, Pileri S. Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects. Cancers (Basel). 2019 Apr 28;11(5):595. doi: 10.3390/cancers11050595. PMID: 31035408; PMCID: PMC6562663. DOI: https://doi.org/10.3390/cancers11050595
Valentini CG, Piciocchi A, Facchetti F, Guolo F, Pulsoni A, Vignetti M, Pagano L. Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey. Blood Adv. 2021 Dec 28;5(24):5608-5611. doi: 10.1182/bloodadvances.2021005802. PMID: 34644376; PMCID: PMC8714711. DOI: https://doi.org/10.1182/bloodadvances.2021005802
Willemze, R., Jaffe, E.S., Burg, G., Cerroni, L., Berti, E., Swerdlow, S.H., Ralfkiaer, E., Chimenti, S., Diaz-Perez, J.L., Duncan, L.M., Grange, F., Harris, N.L., Kempf, W., Kerl, H., Kurrer, M., Knobler, R., Pimpinelli, N., Sander, C., Santucci, M., Sterry, W., Vermeer, M.H., Wechsler, J., Whittaker, S. & Meijer, C.J. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood, 105, 3768–3785. DOI: https://doi.org/10.1182/blood-2004-09-3502
Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, Canninga-van Dijk MR, Carlotti A, Geerts ML, Hahtola S, Hummel M, Jeskanen L, Kempf W, Massone C, Ortiz-Romero PL, Paulli M, Petrella T, Ranki A, Peralto JL, Robson A, Senff NJ, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ; EORTC Cutaneous Lymphoma Group. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008 Jan 15;111(2):838-45. doi: 10.1182/blood-2007-04-087288. Epub 2007 Oct 12. PMID: 17934071. DOI: https://doi.org/10.1182/blood-2007-04-087288
Pemmaraju N, Cuglievan B, Lasky J et al. Efficacy and manageable safety of tagraxofusp in pediatric and adolescent/young adult patients with blastic plasmacytoid dendritic cell neoplasm. Br J Haematol 2023 (submitted).
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
